Appetite for Allergies: Alladapt Banks $119M to Push Immunotherapy through Trials

Alladapt Immunotherapeutics has refilled the bank balance with $119 million in institutional financing from the likes of Novartis, which will be used to follow the biotech’s dream of developing the first FDA-approved therapy to treat the majority of food allergy patients.